title: Should we routinely use mupirocin to prevent staphylococcal infections?
abstract: Routine use of mupirocin to prevent staphylococcal infections is controversial. We assessed attitudes and practices of healthcare professionals attending the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections regarding mupirocin prophylaxis. Eighty percent of participants did not use mupirocin routinely. At the end of the session, 58% indicated they would consider increased use of mupirocin.
authors.affiliation: Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Public Health Service, United States Department of Health and Human Services, Atlanta, Georgia, USA.
authors.forename: V R
authors.initials: VR
authors.lastname: Roth
authors.forename: C
authors.initials: C
authors.lastname: Murphy
authors.forename: T M
authors.initials: TM
authors.lastname: Perl
authors.forename: A
authors.initials: A
authors.lastname: DeMaria
authors.forename: A H
authors.initials: AH
authors.lastname: Sohn
authors.forename: R L
authors.initials: RL
authors.lastname: Sinkowitz-Cochran
authors.forename: W R
authors.initials: WR
authors.lastname: Jarvis
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D003428:Cross Infection / Q000517:prevention & control*; D006801:Humans; D016712:Mupirocin / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity
chemical_list: D000900:Anti-Bacterial Agents; D016712:Mupirocin